The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)
about
Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-CancerNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceGram-negative bacteria facilitate tumor outgrowth and metastasis by promoting lipid synthesis in lung cancer patientsSCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma.EGFR tyrosine kinase inhibitors: difference in efficacy and resistance.[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review.Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
P2860
Q26771116-7CACA9B6-2888-41B0-9B0E-EB902AF8D61AQ28079320-AD55E8B8-39F4-4704-95B6-A47653173F78Q37208788-ADB4DEB5-4A23-4122-A51C-3455E7F6B142Q37457747-8C1B6F6A-9592-47C8-A53F-D9674C5DF670Q38106905-FA07CF44-F5B4-4F33-AF20-96084DC2C8AAQ40530427-715AA102-974C-42A4-B6BD-B0DC4CA71C2CQ40979412-21921EEF-8831-4AF7-A40B-4FBD17DCF017Q51415798-155D46B6-BD37-4834-A8E6-7CE4FAB4EBE7Q52562714-DD154617-DC30-4753-87B9-913DD40F2DA5Q53217202-7BDD56BF-FD29-4873-A2AB-073E13768475Q54667267-5BCA38E1-71E8-4B7D-84A9-FC6233FC831C
P2860
The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@ast
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@en
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@nl
type
label
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@ast
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@en
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@nl
prefLabel
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@ast
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@en
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@nl
P2093
P2860
P3181
P1476
The latest therapeutic strateg ...... small cell lung cancer (NSCLC)
@en
P2093
P2860
P3181
P356
10.1097/JTO.0B013E318174E981
10.3978/J.ISSN.2305-5839.2015.03.60
P407
P577
2015-05-01T00:00:00Z